Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of Tarsus Pharmaceuticals in a report released on Wednesday, February 26th. HC Wainwright analyst O. Livnat anticipates that the company will earn ($0.06) per share for the quarter. HC Wainwright has a "Buy" rating and a $73.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' FY2028 earnings at $5.10 EPS and FY2029 earnings at $6.29 EPS.
A number of other equities research analysts have also weighed in on the stock. Barclays lowered their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Guggenheim restated a "buy" rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a research report on Friday, November 15th. Finally, Oppenheimer increased their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $61.33.
Get Our Latest Research Report on Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Stock Down 4.0 %
Shares of Tarsus Pharmaceuticals stock traded down $1.76 during trading hours on Thursday, reaching $42.72. The company's stock had a trading volume of 736,091 shares, compared to its average volume of 643,788. The company has a market capitalization of $1.64 billion, a P/E ratio of -11.21 and a beta of 1.01. The stock's fifty day simple moving average is $50.97 and its two-hundred day simple moving average is $43.36. Tarsus Pharmaceuticals has a one year low of $20.08 and a one year high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
Several large investors have recently made changes to their positions in the business. Crowley Wealth Management Inc. bought a new position in Tarsus Pharmaceuticals during the fourth quarter valued at about $25,000. GF Fund Management CO. LTD. purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $44,000. R Squared Ltd bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at approximately $53,000. FMR LLC increased its stake in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after purchasing an additional 3,537 shares during the last quarter. Finally, Quarry LP bought a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $166,000. 90.01% of the stock is owned by hedge funds and other institutional investors.
Tarsus Pharmaceuticals Company Profile
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Stories
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
